Newsletter

abstracts

ABSTRACTS guidelines​

Abstracts Submission Period

10 March - 02 June 2025

EXTENDED tO 4 JUNE at 12:00 PM (midday) CEST

Opening: 10 February (10.00am CET)

Closing: 30 April 2026 (11.59pm CET)

Abstracts submission

Click Here

TRAVEL GRANTS

ESDR members may apply for travel grants to attend the ESDR meeting. The deadline for applications is 30 april 2026 (the same date as the abstract deadline). Applicants will be selected by the ESDR Scientific Program Committee. 

The criteria for applications are:
• Aged 40 or under at 1 September 2026
• ESDR Member
• May reside or be working in any country
• Has submitted an abstract to the ESDR 2026 meeting as presenting author

Please complete your application in the abstract submission system before the deadline of 30 April 2026

Submission

Only one paper or poster may be presented by the same author at the meeting, although a presenter may be coauthor of any number of papers. The material should not have been published or presented at any European meeting prior to the date of presentation. It is permissible, however, to have presented the material previously at a regional meeting and to have had it published in abstract form in a publication associated with one of these meetings.

Abstract submissions may only be made through the website. Support is available by contacting the ESDR Office (office [at] esdr.org)

Abstracts Submission Link: https://esdr2026.abstractcentral.com/

Abstract Destination

All abstracts submitted to the ESDR Meeting will be considered for oral presentation at the main ESDR meeting, except those marked for poster presentation by the author. If your abstract is not selected for oral presentation at the main ESDR meeting, you may be invited to give an oral presentation at a satellite meeting of ESDR 2026. In this case you will be contacted directly by the organisers of the satellite meeting.

CATEGORIES

Autoimmune and genetic skin diseases
Cellular and molecular physiopathology of inflammatory skin diseases
Clinical dermatology, case reports and epidemiology
Infectious skin diseases, skin dysbiosis and skin microbiome
Skin ageing, senescence and protective strategies
Skin cancers, pathomechanisms and innovative therapies
State-of-the-art in skin biology and translational skin research
Wound healing and regenerative dermatology

Guidelines

Please complete the steps in the on-line abstract submission procedure on the ESDR abstract submission website adhering to the instructions given there. To submit the abstract text, you must copy your text into the form provided. Do not exceed 2300 characters (including spaces, authors and affiliations).

Abstracts must conform to the following standards:

  • Maximum of 10 co-authors. You can add additional authors on your meeting poster.
  • Please indicate each co-author’s principal affiliation only where possible.
  • DO NOT exceed 2300 characters including spaces (also including title, authors and affiliations). Overly long abstracts may be edited.
  • DO NOT use graphics or tables.
  • DO NOT use subheadings like “RESULTS, DISCUSSION” etc in your text. These will be deleted.
  • DO NOT number sections in your abstract.
  • DO NOT put author names or affiliations in the abstract text. This will help to ensure that your abstract is reviewed fairly.
  • DO NOT use capitals or underline for emphasis in the text. Use the standard Symbol font for Greek and math symbols.
  • DO NOT mention support of work by a research grant.
  • DO NOT include references. These will be deleted.
  • The title must be brief and indicate clearly the nature of the investigation. The title should be upper and lowercase letters. Abbreviations must not be used in the title.
  • Nonproprietary (generic) names should be given the first time a drug is mentioned in the body of the abstract and should be written in small letters. The first letter of a proprietary name is always capitalized, e.g., cyproheptadine (Periactin).
  • The abstract body should be organised as follows:
  1. a sentence describing the purpose of the study;
  2. a statement of experimental design or method used;
  3.  a summary of results, presented in sufficient detail to support the conclusion; and
  4. a statement of conclusions reached.
  •  It is not satisfactory to state “The results will be discussed…” or “Other data will be presented.”

Failure to follow these instructions will result in a low priority score and may cause disqualification of your abstract.

publication of abstracts

Abstracts will be published in the October issue of the Journal of Investigative Dermatology. Late-Breaking abstracts will not be published.

LATE-BREAKING ABSTRACTS

late breaking abstracts Submission Period

24 June to 12 July 2026 at 11:59pm CEST

Submission

The ESDR is accepting late-breaking abstracts from 01 until 18 July 2025. Accepted abstracts will be shown as Electronic Posters. Selected abstracts will be presented in a Concurrent oral session and Poster Walk sessions. You may submit a maximum of one abstract as presenting author (but you may be a co-author of multiple submissions).

Please send your submissions by email to office@esdr.org adhering to the general rules.

At least one author or coauthor must be registered for the ESDR meeting if your abstract is accepted.​

publication of abstracts

Late-Breaking abstracts will not be published.

Guidelines

Your abstract should be submitted as a word document or pdf.

Abstracts must conform to the following standards:

  • Please indicate each co-author’s principal affiliation only where possible.
  • DO NOT use graphics or tables.
  • DO NOT use subheadings like “RESULTS, DISCUSSION” etc in your text. These will be deleted.
  • DO NOT number sections in your abstract.
  • DO NOT use capitals or underline for emphasis in the text. Use the standard Symbol font for Greek and math symbols.
  • DO NOT mention support of work by a research grant.
  • DO NOT include references. These will be deleted.
  • The title must be brief and indicate clearly the nature of the investigation. The title should be upper and lowercase letters. Abbreviations must not be used in the title.
  • Nonproprietary (generic) names should be given the first time a drug is mentioned in the body of the abstract and should be written in small letters. The first letter of a proprietary name is always capitalized, e.g., cyproheptadine (Periactin).
  • The abstract body should be organised as follows:
  1. a sentence describing the purpose of the study;
  2. a statement of experimental design or method used;
  3.  a summary of results, presented in sufficient detail to support the conclusion; and
  4. a statement of conclusions reached.
  •  It is not satisfactory to state “The results will be discussed…” or “Other data will be presented.”

Failure to follow these instructions will result in a low priority score and may cause disqualification of your abstract.

more information coming soon

grants/scholarships

text

text

Submission

....